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Abstract
 Background—Access to hepatitis B viral load (VL) testing is poor in sub-Saharan Africa 
(SSA) due to economic and logistical reasons.
 Objectives—To demonstrate the feasibility of testing dried blood spots (DBS) for hepatitis B 
virus (HBV) VL in a laboratory in Lusaka, Zambia, and to compare HBV VLs between DBS and 
plasma samples.
 Study design—Paired plasma and DBS samples from HIV-HBV co-infected Zambian adults 
were analyzed for HBV VL using the COBAS AmpliPrep/COBAS TaqMan HBV test (Version 
2.0) and for genotype by direct sequencing. We used Bland-Altman analysis to compare VLs 
between sample types and by HBV genotype. Logistic regression analysis was conducted to assess 
the probability of an undetectable DBS result by plasma VL.
 Results—Among 68 participants, median age was 34 years, 61.8% were men, and median 
plasma HBV VL was 3.98 log IU/ml (interquartile range, 2.04–5.95). Among sequenced viruses, 
28 were genotype A1 and 27 were genotype E. Bland-Altman plots suggested strong agreement 
between DBS and plasma VLs. DBS VLs were on average 1.59 log IU/ml lower compared to 
plasma with 95% limits of agreement of −2.40 to −0.83 log IU/ml. At a plasma VL ≥2,000 IU/ml, 
the probability of an undetectable DBS result was 1.8% (95% CI: 0.5–6.6). At plasma VL ≥20,000 
IU/ml this probability reduced to 0.2% (95% CI: 0.03–1.7).
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 Conclusions—In a Zambian laboratory, we observed strong agreement between DBS and 
plasma VLs and high sensitivity in DBS at plasma VL ≥2,000 IU/ml. As HBV treatment expands, 
DBS could increase access to HBV VL testing in SSA settings.
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 Background
Worldwide approximately 240 million individuals are chronically infected with hepatitis B 
virus (HBV), with the highest burden in Asia and sub-Saharan Africa (SSA).1 Each year, 
650,000 individuals die from complications of chronic HBV infection including 
decompensated cirrhosis and hepatocellular carcinoma.2 For individuals with chronic HBV 
infection, several potent nucleoside/nucleotide analogues can durably suppress viral 
replication and reduce liver-related complications and mortality. Eligibility for these 
antiviral agents depends on HIV-infection status, serologic markers of disease activity, serum 
transaminases, liver fibrosis stage, and HBV viral load.
Despite its high burden, chronic HBV infection is often overlooked in low and middle-
income countries (LMIC) where access to both screening and treatment may be limited 
compared with upper-income settings. The World Health Assembly — the policymaking 
arm of the World Health Organization (WHO) — has called for increased awareness of viral 
hepatitis and improved access to diagnosis and treatment, specifically in LMIC. In 2015, the 
WHO published its first guidelines for treatment of chronic HBV infection.3 Implementation 
of these guidelines in SSA settings will be challenging as access to essential diagnostic and 
monitoring tests are limited. Outside of provincial or national laboratories, few facilities 
have capacity for HBV serologic testing and even fewer have platforms to measure HBV 
viral load. Where infrastructure is lacking, challenges in processing and transporting plasma 
or serum blood samples to central laboratories undermines patient access to critical tests that 
guide HBV management. Dried blood spots (DBS) offer a potential alternative to plasma or 
serum samples for use in HBV management. Staff with minimal training can collect DBS 
after which blood samples remain relatively stable at room temperature. Historically DBS 
have been used to collect blood for genetic tests in newborn screening programs in upper-
income settings. In SSA, DBS collection plays a critical role in HIV care programs where 
they are routinely collected from HIV-exposed infants for HIV proviral DNA testing using 
automated assays.4 To date, HBV testing with DBS has been limited to research settings, 
although laboratories in North America, Europe, and Africa have demonstrated the 
feasibility of measuring both serologic and virologic markers of chronic HBV infection.5–8
 Objectives
Building on prior work in this area, we compared HBV viral loads in paired DBS and 
plasma samples using commercially available tests in a Zambian laboratory that had 
experience in HIV viral load and DBS testing.
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HIV-infected adults (18+ years old) who were eligible for antiretroviral therapy, but had not 
yet initiated, were enrolled in a prospective cohort in two public sector clinics in Zambia’s 
capital Lusaka, funded through the International Epidemiologic Databases to Evaluate AIDS 
in Southern Africa.9 The study’s aim was to evaluate the prevalence, risk factors, and 
outcomes of liver fibrosis. As part of the enrollment procedures, all participants were 
screened for hepatitis B virus (HBV) co-infection using a rapid point-of-care test (Determine 
HBsAg, Alere, Massachusetts, USA).
 Study procedures
From HBsAg-positive patients, a blood sample was collected in an EDTA-containing blood 
tube. Within 6 hours of collection plasma was separated from blood and stored at −80 °C. 
On the same day, according to WHO guidelines for early infant HIV diagnosis, we used 
finger prick sampling in the clinic to collect whole blood spots (50 μL per spot) on 
unperforated Whatman 903 protein saver DBS cards (GE Healthcare, New Jersey, USA). 
After collection, cards were dried in a horizontal position in the clinic for 1–3 days after 
which they were inserted into air impermeable foil bags containing 2–3 desiccant sachets 
and stored at the Centre for Infectious Disease Research in Zambia (CIDRZ) central 
laboratory at -80 °C for 1–6 months. CIDRZ central laboratory serves as the reference 
laboratory for HIV care and treatment programs in 4 of 10 Zambian provinces and tests 
approximately 500 DBS for HIV proviral DNA and 800 plasma samples for HIV viral load 
each month.
In the laboratory, we prepared diluted DBS samples to obtain robust estimates of the 
detection limits of HBV viral load testing in DBS. All original plasma samples were diluted 
serially with Basematrix 53 (SeraCare, Life Sciences, Massachusetts, USA) to create paired 
plasma/DBS samples with relatively low viral loads (<20 IU/ml to <20,000 IU/ml). After 
quantifying the viral load in the diluted samples, we made 50 μL spots on DBS cards using a 
pipette and left them to dry for at least 12 hours in a horizontal position.
We punched two spots from each DBS card, and suspended both in 1.2 ml of sample pre-
extraction (SPEX) buffer (Roche Molecular Systems, Pleasanton, California, USA). 
Therefore, DBS blood was diluted by a ratio of 1:12 during elution. Tubes were incubated at 
56°C for 10 minutes with continuous agitation (as recommended in Roche’s package insert 
for qualitative HIV proviral DNA testing using DBS). We used 650 μL of DBS eluate to 
detect and quantify HBV DNA by real-time polymerase chain reaction (Roche COBAS 
AmpliPrep/COBAS TaqMan HBV test, version 2.0, Pleasanton, California, USA). 
According to the manufacturer, the test has a viral load range from 20 to 170,000,000 IU/ml. 
We assigned DBS samples a viral load of 10 IU/ml if virus was detectable but not 
quantifiable (<20 IU/ml).
We also genotyped HBV using an in-house assay based on direct sequencing. We extracted 
HBV DNA from serum samples using the QIAamp DNA mini kit (Qiagen, Hilden, 
Germany), amplified the polymerase and surface antigen genes using publically available 
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PCR primer sets, 10,11 and purified it using QIAquick PCR purification kit (Qiagen, Hilden, 
Germany). Sanger sequencing was performed using an AB3130 genetic analyzer (Life 
Technologies, California, USA) and nucleotide sequences were analyzed with Sequencher 
version 5.0 (Gene Codes Corporation, Michigan, USA). Geno2Pheno 
(www.geno2pheno.org) was used to predict HBV genotypes.
 Statistical analyses
In our primary analysis, we compared log10 HBV viral loads between original plasma and 
original DBS samples by genotype using the Wilcoxon rank sum test. Viral loads were also 
compared between genotypes. We used Bland-Altman analysis to compare viral loads on a 
logarithmic scale obtained from DBS and plasma to visually compare the relationship 
between sample types. This methodology assesses the agreement between two clinical 
measures and reduces the potential bias of correlation coefficients. We also repeated this 
separately for each genotype. Using original plasma and DBS samples, we calculated the 
mean differences (with 95% confidence intervals) in HBV viral load.
Using all samples (original and diluted), we estimated the probability of an undetectable 
HBV DNA in DBS samples using logistic regression and considering plasma results as the 
gold standard. We plotted the probability (with 95% confidence interval) of an undetectable 
DBS result according to plasma viral load. In a second logistic regression analysis among 
samples with HBV DNA detected in DBS, we estimated the probability of a non-
quantifiable DBS result in relation to plasma HBV DNA. Statistical analyses were 
performed using Stata version 13 (Statacorp, College Station, Texas, USA). The ethics 
committees of the University of Zambia (Lusaka, Zambia) and the University of North 
Carolina at Chapel Hill (North Carolina, USA) approved the study. All patients provided 
written informed consent.
 Results
Of 798 patients screened for HBV infection, 98 (12.2%) were HBsAg-positive. Among 
HBsAg-positive patients, paired plasma and DBS samples from 68 patients with detectable 
plasma HBV DNA were included in this study. The median age of patients included in the 
study was 34 years (interquartile range [IQR], 29–37), 61.8% were men, median CD4+ 
count was 210 (IQR, 112–378), and 47.0% were hepatitis B e antigen positive. Original 
plasma samples had a median HBV viral load of 3.98 log10 IU/ml (interquartile range, 2.04–
5.95). We successfully sequenced 55 patients’ viruses and observed that 28 were genotype 
A1 and 27 were genotype E. Median log10 HBV viral loads were 4.1 IU/ml (IQR, 2.2–6.1) 
in DBS and 5.3 IU/ml (IQR, 3.7–7.8) in plasma for genotype A1 and 4.7 IU/ml (IQR, 3.6–
6.0) in DBS and 6.2 IU/ml (IQR, 5.3–7.8) in plasma for genotype E virus (Figure 1). For 
both sample types, there was no statistical difference in viral load between genotypes 
(plasma, P=0.33; DBS, P=0.60).
HBV DNA was not detected in 6 (8.8%) original DBS samples (1 genotype A1, 1 genotype 
E, 4 non-genotyped), despite detectable viral loads in their corresponding plasma samples. 
Bland-Altman plots for all paired samples and plots stratified by genotype suggested strong 
agreement between the two sample types (Figures 2, 3A, and 3B). Viral loads in original 
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DBS samples were on average 1.59 log IU/ml (95% CI: 1.48 to 1.70) lower than 
corresponding plasma samples. The limits of agreement between DBS and plasma were 
−2.40 to −0.83 log IU/ml. HBV viral loads in DBS and plasma were also highly correlated 
(correlation coefficient, 0.966; P<0.001). When stratified by genotype, we observed similar 
average differences between DBS and plasma viral loads (A1: 1.56 log IU/ml, 95% CI: 1.44 
to 1.69; E: 1.66 log IU/ml, 95% CI: 1.42 to 1.89; Figure 3).
In addition to the 68 original samples, 81 paired diluted plasma and DBS samples were 
included in the logistic regression analysis. The sensitivity of the assay using DBS increased 
with increasing HBV viral load (Figure 4A). The probability of a undetectable DBS result at 
a plasma viral load of 200 IU/ml was 13.8% (95% CI: 7.7–23.7) but this dropped to 1.8% 
(95% CI: 0.5–6.6) when a 2,000 IU/ml threshold was used and 0.2% (95% CI: 0.03–1.7) at 
20,000 IU/ml. In the second logistic regression model we found the detection limit for 
quantification of HBV viral load in DBS to be approximately 3 log IU/ml. The probability of 
failing to quantify HBV viral load increased from 2.5% at 3.81 log IU/ml to 97.5% at 2.34 
log IU/ml (Figure 4B).
 Discussion
In a reference laboratory in Lusaka, Zambia, we used commercially available assays to 
demonstrate the feasibility and performance of HBV viral load testing of DBS samples that 
were collected by finger stick in field settings. There was a strong agreement between paired 
DBS and plasma samples over a dynamic range of viral loads for both HBV genotypes A1 
and E viruses, the most common ones in Southern Africa. At recommended treatment 
thresholds, HBV DNA was detectable >98% of the time in DBS. These results suggest that 
DBS may be a useful specimen type for HBV viral load testing in LMIC.
This Zambian study builds on data from high-income settings where DBS have been 
investigated as a sample type for HBV testing. Similar to our findings, in a laboratory in 
France, Mohamed and colleagues compared HBV viral loads in plasma with DBS. When the 
corresponding plasma viral load was ≥2,000 IU/ml, sensitivity in DBS was 100% (n=50 
samples), similar to the 98.2% we observed. After diluting samples to lower levels of 
viremia, they estimated a limit of detection in DBS of 914.1 IU/ml (standard deviation, 
157.8).7 Similar to our results, Mohamed and others reported that DBS samples had 
consistently lower HBV viral loads compared to plasma, with those differences ranging from 
0.65 to 1.0 log IU/ml.6,7 The average difference in viral load between sample types in our 
study (1.59 log IU/ml) was not unexpected since DBS have smaller input volumes of 75–100 
μL of whole blood (approximately half of which is comprised of plasma) versus 650 μL used 
in plasma testing. To attenuate the difference in sample volumes we punched and eluted two 
blood spots per test. Suboptimal elution of nucleic acids from the filter paper is another 
explanation for the difference between DBS and plasma viral loads. In this study, we used 
manual elution methods but other studies7 have utilized automated platforms to optimize the 
procedure.
Thousands of HIV DNA tests are performed each year using DBS; however, this is the first 
study in SSA to investigate HBV viral load using DBS. Our inclusion of two predominant 
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genotypes supports the assay’s robustness to settings with diverse circulating HBV viruses. 
We also note several limitations. We validated DBS for HBV viral load but did not include 
serologic tests for HBV such as HBsAg or hepatitis B e antigen, which would have 
strengthened our study. Although the majority of DBS were collected in field settings by 
finger prick, the laboratory where sample processing, storage, and testing occurred is one of 
the most advanced in Zambia, limiting the generalizability of our results to African settings 
with reduced laboratory capacity. HBV samples came from an HIV co-infected cohort 
whose characteristics may differ from HBV mono-infected patients, although this should not 
have affected the comparison between sample types. Finally, we did not ascertain the 
hepatitis delta virus status of patients, something that may alter HBV replication but would 
not have affected this validation study.
HBV diagnosis and treatment have become increasing priorities in LMIC; therefore, our 
study has important implications. Our experience suggests that DBS could increase access to 
HBV viral load testing, particularly in laboratories with the equipment and experience for 
HIV viral load and DBS testing. DBS are simple to collect, store, and transport, overcoming 
many of the challenges of specimen handling in rural settings. The reduced sensitivity of 
DBS would not affect initial clinical decision-making as HBV viral load thresholds for 
treatment initiation in international guidelines range from 2,000–20,000 IU/ml. However, 
during antiviral treatment DBS tests would have inadequate detection thresholds for 
monitoring at low viral loads.
In addition to chronic HBV infection management, DBS could also be used in 
epidemiologic studies in endemic settings where such data are rare. During many nationally 
representative surveys in SSA, DBS are collected for the purpose of HIV testing. These 
samples could be similarly utilized to describe the burden of HBV in these settings. In our 
Zambian cohort, the most common HBV genotype was A1, which has been linked with high 
rates of HCC in SSA.12 This further supports the need for early diagnosis and viral load 
testing for chronic HBV infection.
Although they are a promising alternative sample type for viral load testing, DBS can be 
logistically challenging to utilize for clinical care in SSA settings. In HIV proviral DNA 
testing for early infant diagnosis, the turnaround time from sample collection to results 
delivery can range from weeks to months. Delays are generally not due to the time it takes 
the lab to test the sample, but rather due to the time and logistics involved in transportation 
of the specimen and results to and from field sites. Programs considering DBS for HBV viral 
load testing should have systems to generate timely results to inform clinical decision-
making.13
In summary, we demonstrated the feasibility of using DBS for HBV viral load testing in a 
laboratory in Zambia using automated assays made available through the HIV care and 
treatment program. As HBV diagnosis and treatment increases in LMIC, DBS may be an 
alternative sampling approach to increase access to HBV viral load testing.
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• Dried blood spots (DBS) were tested in a Zambian lab for hepatitis B 
viral load.
• There was strong agreement between HBV viral loads in DBS and 
plasma samples.
• DBS viral loads were on average 1.5 log IU/ml lower compared to 
plasma viral loads.
• HBV was detected in DBS 98.2% of the time at a plasma viral load 
≥2,000 IU/ml.
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Hepatitis B viral loads from paired plasma and dried blood spot samples collected in 
Zambia, by genotype
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Bland-Altman plot comparing hepatitis B viral loads between paired plasma and dried blood 
spot samples collected in clinics in Lusaka, Zambia
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Figure 3A. Bland-Altman plot comparing hepatitis B genotype A1 viral loads between 
paired plasma and dried blood spot samples collected in clinics in Lusaka, Zambia
Figure 3B. Bland-Altman plot comparing hepatitis B genotype E viral loads between paired 
plasma and dried blood spot samples collected in clinics in Lusaka, Zambia
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Figure 4A. Probability (with 95% confidence interval) of an undetectable hepatitis B viral 
load in a dried blood spot according to the plasma viral load
Figure 4B. Probability (with 95% confidence interval) of a non-quantifiable hepatitis B viral 
load in a dried blood spot according to the plasma viral load
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